This program was developed and planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.
Learning Objectives:
Understand the mechanisms and clinical outcomes used to evaluate emerging biologic therapies in myasthenia gravis
Explore novel biologic strategies beyond FcRn inhibition, including complement-targeted and CAR-T cell therapies
Assess the clinical application and evolving role of FcRn inhibitors in the treatment of myasthenia gravis
